Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Region Hovedstadens forskningsportal Forside
Dansk
English
Søg efter indhold i Region Hovedstadens forskningsportal
Forside
Hospitaler/Afdelinger
Forskere
Publikationer
Aktiviteter
Priser
Clinical pharmacology of imeglimin for the treatment of type 2 diabetes
Karl Sebastian Johansson
,
Andreas Brønden
, Filip Krag Knop
,
Mikkel Bring Christensen
Steno Diabetes Center Copenhagen
Center for Klinisk Metabolisk Forskning
Klinisk Farmakologisk Afdeling
21
Citationer (Scopus)
Oversigt
Fingeraftryk
Fingeraftryk
Dyk ned i forskningsemnerne om 'Clinical pharmacology of imeglimin for the treatment of type 2 diabetes'. Sammen danner de et unikt fingeraftryk.
Sorter
Vægt
Alfabetisk
Keyphrases
Clinical Pharmacology
100%
Type 2 Diabetes Prevention
100%
Imeglimin
100%
Type 2 Diabetes Mellitus (T2DM)
66%
Hemoglobin A1c (HbA1c)
33%
Twice Daily
33%
Dipeptidyl peptidase-4 (DPP-4)
33%
Placebo
16%
Pharmacotherapy
16%
Adverse Effects
16%
Embase
16%
Plasma Glucose
16%
Clinical Data
16%
Once-daily
16%
Type 2 Diabetic Patients
16%
Metformin
16%
Clinical Development
16%
Clinical Efficacy
16%
PubMed
16%
Monotherapy
16%
Literature Search
16%
Clinical Trials
16%
Mechanism of Action
16%
Glucagon-like
16%
Glucose-lowering Drugs
16%
Mode of Action
16%
Add-on Therapy
16%
Preclinical Data
16%
Treatment Options
16%
Insulin Secretion
16%
Expert Opinion
16%
Mitochondrial Function
16%
Oral Glucose Tolerance Test
16%
Cardiovascular Effects
16%
Area Cover
16%
OGTT
16%
Gastrointestinal Distress
16%
Glycated Hemoglobin A1c
16%
Peroxisome Proliferator-activated Receptor
16%
Pancreatic β-cells
16%
Sitagliptin
16%
Diabetes Type 2
16%
Oral Antidiabetics
16%
Oral Antidiabetic Agents
16%
Glucagon-like peptide-1 Receptor (GLP-1R)
16%
High-sucrose Diet
16%
STZ Streptozotocin
16%
Permeability Transition Pore
16%
1 Receptor
16%
Clinical Safety
16%
Sodium-glucose Cotransporter 2 (SGLT2)
16%
Action Efficacy
16%
Sodium-glucose Transport Protein 2
16%
AUC Area under the Curve
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Pharmacology
100%
Imeglimin
100%
Maturity Onset Diabetes of the Young
100%
Hemoglobin A1c
37%
Glucose
37%
Placebo
12%
Oral Antidiabetic Agent
12%
Metformin
12%
Monotherapy
12%
Pharmacotherapy
12%
Prevalence
12%
Clinical Trial
12%
Add on Therapy
12%
Gastrointestinal Symptom
12%
Streptozotocin
12%
Sitagliptin
12%
Glucagon-Like Peptide 1 Receptor
12%
Dipeptidyl Peptidase IV
12%
Insulin
12%
Peroxisome Proliferator Activated Receptor
12%
Peroxisome Proliferator Activated Receptor Gamma
12%
Sodium Glucose Cotransporter
12%
Mode of Action
12%
Sucrose
12%
Adverse Effect
12%